HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN Congressional Reports On DSHEA, Pearson, Strategic Plan Slated

This article was originally published in The Tan Sheet

Executive Summary

The Center for Food Safety & Applied Nutrition will submit reports to Congress this fiscal year on the cost of addressing various dietary supplement issues.

You may also be interested in...



CFSAN

Ephedra strategy, dietary supplement labeling guide and research plan made "B" list priorities for 2001, foods center says in mid-year accomplishments paper issued July 10. Actions are not expected to be completed by end of FY 2001, as originally proposed (1"The Tan Sheet" Jan. 15, p. 3). Urgent matters such as BSE, food allergens, genetically modified corn forced CFSAN to reframe priorities for fiscal year, center explains

Government Reform Cmte. Ephedra Hearing Still Possible Pending FDA Stance

The House Government Reform Committee still is considering holding a hearing on FDA's position regarding ephedrine alkaloid-containing dietary supplements.

Ephedra/AER Causality Link Not Possible - Cantox/CRN

Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.

Related Content

Topics

UsernamePublicRestriction

Register

RS131325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel